PharmAthene (PIP) Given News Sentiment Rating of 0.25
Media stories about PharmAthene (NYSE:PIP) have trended positive on Tuesday, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. PharmAthene earned a news sentiment score of 0.25 on Accern’s scale. Accern also gave media headlines about the financial services provider an impact score of 47.7748202261986 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Shares of PharmAthene (NYSE PIP) opened at 0.65 on Tuesday. The company has a 50-day moving average of $0.77 and a 200-day moving average of $2.08. PharmAthene has a one year low of $0.47 and a one year high of $3.50.
TRADEMARK VIOLATION WARNING: This report was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.thecerbatgem.com/2017/10/03/pharmathene-pip-given-news-sentiment-rating-of-0-25.html.
PharmAthene Company Profile
Pharmathene, Inc (Pharmathene) is a biodefense company. The Company is focused on the development of medical counter measures against biological and chemical threats. The Company is involved in the development of two next generation anthrax vaccines. The Company’s anthrax vaccines use recombinant protective antigen (rPA) manufacturing processes.
Receive News & Stock Ratings for PharmAthene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmAthene Inc. and related stocks with our FREE daily email newsletter.